Please use this identifier to cite or link to this item:
Title: Immune response generated with the administration of autologous dendritic cells pulsed with an allogenic tumoral cell lines lysate in patients with newly diagnosed DIPG
Author: Benítez-Ribas, Daniel
Cabezón Cabello, Raquel
Flórez Grau, Georgina
Molero, Mari Carmen
Puerta, Patricia
Guillen, Antonio
González-Navarro, Europa Azucena
Paco Mercader, Sonia
Carcaboso, Ángel M.
Santa-Maria Lopez, Vicente
Cruz Martínez, Ofelia
Torres Gómez-Pallete, Carmen de
Salvador, Noelia
Juan, Manel
Mora Graupera, Jaume
Morales La Madrid, Andrés
Keywords: Immunoteràpia
Cèl·lules dendrítiques
Dendritic cells
Issue Date: 26-Apr-2018
Publisher: Frontiers Media
Abstract: Background and objective. Diffuse intrinsic pontine glioma (DIPG) is a lethal brainstem tumor in children. Dendritic cells (DCs) have T-cell stimulatory capacity and, therefore, potential antitumor activity for disease control. DCs vaccines have been shown to reactivate tumor-specific T cells in both clinical and pre-clinical settings. We designed a phase Ib immunotherapy (IT) clinical trial with the use of autologous dendritic cells (ADCs) pulsed with an allogeneic tumors cell-lines lysate (ATCL) in patients with newly diagnosed DIPG after irradiation (RT). Methods. Nine patients with newly diagnosed DIPG met enrollment criteria. Autologous dendritic cell vaccines (ADCV) were prepared from monocytes obtained by leukapheresis. Five ADCV doses were administered intradermally during induction phase. In the absence of tumor progression, patients received 3 boosts of tumor lysate every three months during the maintenance phase. Results. Vaccine fabrication was feasible in all patients included in the study. Non-specific KLH (9/9 patients) and specific (8/9 patients) antitumor response was identified by immunologic studies in peripheral blood mononuclear cells (PBMC). Immunological responses were also confirmed in the T lymphocytes isolated from the cerebrospinal fluid (CSF) of 2 patients. Vaccine administration resulted safe in all patients treated with this schema. Conclusions. These preliminary results demonstrate that ADCV preparation is feasible, safe and generate a DIPG-specific immune response detected in PBMC and CSF. This strategy shows a promising backbone for future schemas of combination immunotherapy.
Note: Reproducció del document publicat a:
It is part of: Frontiers in Oncology, 2018, vol. 8, p. 127
Related resource:
ISSN: 2234-943X
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)

Files in This Item:
File Description SizeFormat 
679832.pdf595.22 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons